Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say

Executive Summary

The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product
Advertisement

Related Content

HGS Submits BLA For Interferon Zalbin For Hepatitis C
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain
ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
Potential HCV Blockbuster, Strong Fundraising Place Vertex In Enviable Position
Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

Topics

Advertisement
UsernamePublicRestriction

Register

PS050707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel